Journal of Clinical Trials
Open Access

Hisao Ogawa

Publications

• Research Article
  The Changes of Biomarkers by Telmisartan and their Significance in Cardiovascular Outcomes: Design of a Trial of Telmisartan Prevention of Cardiovascular Diseases (ATTEMPT-CVD)
  
  Author(s): Hirofumi Soejima, Hisao Ogawa, Osamu Yasud, Shokei Kim-Mitsuyam, Kunihiko Matsui, Koichi Nod, Megumi Yamamuro, Eiichiro Yamamoto, Keiichiro Kataok, Hideaki Jinnouchi and Taiji Sekigami Hirofumi Soejima, Hisao Ogawa, Osamu Yasud, Shokei Kim-Mitsuyam, Kunihiko Matsui, Koichi Nod, Megumi Yamamuro, Eiichiro Yamamoto, Keiichiro Kataok, Hideaki Jinnouchi and Taiji Sekigami
  
  Objective: Angiotensin II receptor blocker (ARB) has become first-line agent for the treatment of hypertensive patients because they are associated with an excellent effect for blood pressure control and a lower rate of occurrence of adverse reactions. To our knowledge, there is no report of the large-scale study that measures biomarkers in 1000 or more patients for long follow-up period. To compare the effects of ARB therapy and that of standard therapy except ARB on the changes of biomarker levels and the incidence of cardiovascular events, a trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD) was planned. Urinary albumin creatinine rates, plasma brain natriuretic peptide, serum high sensitivity c-reactive protein, urinary 8-hydroxy-deoxy-guanosine, serum adiponectin, and high-molecular weight adiponectin were selected as biomarkers. These biomarkers are .. View More»
  DOI: 10.4172/2167-0870.1000162

  Abstract

Relevant Topics